AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
09.06.2025 07:28:15
|
Sanofi Speeds Up Global Beyfortus Shipments Ahead Of 2025-2026 RSV Season
(RTTNews) - Sanofi S.A. (SNYNF, SNY) is speeding up the global distribution of Beyfortus (nirsevimab) to ensure healthcare providers have access well in advance of the 2025-2026 RSV season. Shipments will begin in early third quarter, months ahead of the typical RSV season, which runs from November to March. The proactive approach helps providers prepare for immunizations in the early fall and ensures a steady supply, the French drug major said in a statement on Monday.
Since its launch, Beyfortus has remained in high demand as the only RSV protection designed for all infants, offering strong and lasting efficacy, the company said.
To meet growing needs, Sanofi, in partnership with AstraZeneca, has significantly increased production, tripling capacity and doubling manufacturing sites since 2023. Supply for the upcoming season already matches last year's total distribution, with ongoing production ensuring continued availability.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
30.07.25 |
Gute Stimmung in New York: NASDAQ 100 zum Ende des Mittwochshandels im Plus (finanzen.at) | |
30.07.25 |
Börse New York in Grün: NASDAQ 100 am Nachmittag auf grünem Terrain (finanzen.at) | |
30.07.25 |
Handel in New York: NASDAQ 100 mittags mit Zuschlägen (finanzen.at) | |
30.07.25 |
Freundlicher Handel in New York: NASDAQ 100 liegt zum Start im Plus (finanzen.at) | |
29.07.25 |
Schwache Performance in New York: NASDAQ 100 beendet den Dienstagshandel im Minus (finanzen.at) | |
29.07.25 |
Kaum Veränderungen: NASDAQ 100 im Seitwärtstrend (finanzen.at) | |
29.07.25 |
Handel in New York: NASDAQ 100 liegt im Plus (finanzen.at) | |
29.07.25 |
Freundlicher Handel in New York: NASDAQ 100-Anleger greifen zum Start zu (finanzen.at) |
Analysen zu Sanofi S.A. (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 66,00 | 3,94% |
|
Sanofi S.A. (spons. ADRs) | 41,20 | -1,90% |
|
Sanofi S.A. | 79,99 | -6,23% |
|